HOLX : Summary for Hologic, Inc. - Yahoo Finance

U.S. Markets closed

Hologic, Inc. (HOLX)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
40.82+0.52 (+1.29%)
At close: 4:00PM EST
People also watch
ISRGHSICXRAYVARIDXX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close40.30
Open40.34
Bid35.04 x 100
Ask42.50 x 100
Day's Range40.20 - 40.83
52 Week Range32.64 - 41.24
Volume2,309,211
Avg. Volume2,506,501
Market Cap11.4B
Beta0.62
PE Ratio (TTM)34.89
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Hologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : February 21, 2017
    Capital Cube5 days ago

    Hologic, Inc. breached its 50 day moving average in a Bullish Manner : HOLX-US : February 21, 2017

    Categories: ETFs Yahoo Finance Click here to see latest analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Hologic, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)

  • PR Newswire11 days ago

    FDA Grants PMA Approval for Hologic's Aptima® Hepatitis C Quant Dx Assay

    MARLBOROUGH, Mass., Feb. 15, 2017 /PRNewswire/ -- Hologic, Inc. (HOLX) announced today that the United States Food and Drug Administration (FDA) has granted PMA approval for the Company's hepatitis C virus (HCV) assay for quantitation of HCV viral load and confirming active HCV infection on the fully automated Panther® system. "HCV therapeutic options continue to evolve rapidly with highly effective antiviral medications that are transforming treatment of the disease, with cure rates above 90%," said Tom West, president, Diagnostic Solutions Division at Hologic.

  • Investopedia11 days ago

    Hologic to Acquire Cynosure for $1.65 Billion

    Hologic is acquiring Cynosure to expand into the growing medical aesthetics field.